Edwards Lifesciences
Clinical trials sponsored by Edwards Lifesciences, explained in plain language.
A medical device company focused on heart valves and hemodynamic monitoring.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Heart shunt shows promise for easing heart failure symptoms Results expected Nov 2026 (estimated)
- New heart valve registry tracks Long-Term performance Results expected Dec 2026 (estimated)
- New heart valve trial offers hope for patients with rare congenital defects Results expected Dec 2026 (estimated)
- New Catheter-Based valve repair could help heart patients avoid surgery Results expected Dec 2026 (estimated)
- New heart valve fix offers hope for those too sick for surgery Results expected Feb 2027 (estimated)
-
Can a tiny clip seal a heart pouch and prevent strokes?
Disease control Not yet recruitingThis study is testing a device called the ECLIPTIS clip, which is placed during open-heart surgery to close off the left atrial appendage—a small pouch in the heart where blood can pool and form clots that may cause strokes. The trial will enroll about 168 adults who are already …
Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New heart valve aims to improve tricuspid replacement outcomes
Disease control Not yet recruitingThis study is testing a new artificial heart valve, called the TRIFORMIS RESILIA, for people who need their tricuspid valve replaced. The tricuspid valve controls blood flow between two right heart chambers. Researchers will follow 75 adults who receive this valve during surgery …
Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New heart valve offers hope for High-Risk patients
Disease control Not yet recruitingThis study tests a new heart valve (SAPIEN X4) in 125 people with mitral valve disease who are too high-risk for open-heart surgery. The valve is placed using a thin tube through a blood vessel, avoiding major surgery. The goal is to see if the valve is safe and improves heart fu…
Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC